[Clinical Features and Therapeutic Efficacy in Adult Acute Lymphoblastic Leukemia with t (1; 19) (E2A-PBX1)].

To explore the clinical features and therapeutic efficacy in adult ALL patients with t (1; 19) (E2A-PBX1). The clinic data of 19 adult ALL patients with t (1; 19) (E2A-PBX1) in our hospital from Nov. 22, 2010 to Apr. 4, 2018 were collected. The clinical features,complete remission (CR) rate, overall survival (OS) rate and relapse-free survival (RFS) rate of patients received chemotherapy and chemotherapy+HSCT were analyzed. In all the 19 patients, the median age was 24 (14-66), median WBC count was 16.47×109 (1.8-170.34)/L, median Hb level was 98 (65-176) g/L, median Plt count was 50 (15-254)×109/L. Pre B-ALL were 17 cases (89.5%), and common B-ALL were 2 cases (10.5%). Patients received the induction therapy, the overall CR rate was 94.7%, one course CR rate was 94.7%, 4 year OS rate was 47.1% and RFS rate was 43.3%. The OS rate and RFS rate of patients received transplantation were slightly higher than those of patients not received transplantation (OS: 62.5% vs 36.7%) (P=0.188)；RFS (62.5% vs 38.9%) (P=0.166). Most adult ALL patients with t (1; 19) (E2A-PBX1) is Pre B-ALL by Immunophenotyping, as compared with the pediatric patients, the therapeutic efficacy for adult patients with t (1; 19) (E2A-PBX1) is worsen, therefore, stem cell transplantation is still acquired for better long term survival. 伴t（1；19）（E2A-PBX1）的成人急性淋巴细胞白血病的临床特点及疗效分析. 探讨伴t（1；19）（E2A-PBX1）成人急性淋巴细胞白血病（ALL）的临床特点及疗效. 收集2010年11月22日至2018年4月11日我中心收治的19例伴t（1；19）（E2A-PBX1）初治ALL患者的临床资料，分析患者的临床资料特点、化疗及化疗+造血干细胞移植的完全缓解率（CR）、总生存（OS）和无复发生存（RFS）. 19例患者中位年龄24岁（14-66岁），男女比例为0.73∶1。中位白细胞数16.47×109（1.8-170.34）/L， 中位血红蛋白98（65-176）g/L，中位血小板数50（15-254）×109/L。免疫分型Pre B-ALL 17例（89.5%），Common B-ALL 2例（10.5%）。总体CR率94.7%，1个疗程CR率94.7%, 4年总生存率47.1%，4年无复发生存率43.3%。造血干细胞移植组患者总生存及无复发生存略高于非移植组患者OS（62.5% vs 36.7%）（P=0.188）；RFS（62.5% vs 38.9%）（P=0.166）. 成人伴t（1；19）（E2A-PBX1）阳性的ALL患者主要表现为Pre B-ALL，与儿童同类患者疗效比较，疗效较差，造血干细胞移植可提高患者疗效.